Short Interest in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Expands By 114.6%

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the target of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 80,248 shares, an increase of 114.6% from the April 30th total of 37,392 shares. Based on an average daily volume of 114,555 shares, the short-interest ratio is currently 0.7 days. Currently, 0.2% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NBTX. Millennium Management LLC acquired a new position in Nanobiotix in the 4th quarter valued at approximately $390,000. Marshall Wace LLP acquired a new position in Nanobiotix in the 4th quarter valued at approximately $220,000. Optiver Holding B.V. acquired a new position in Nanobiotix in the 3rd quarter valued at approximately $101,000. Finally, Royal Bank of Canada increased its stake in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Stock Down 5.9%

Nanobiotix stock traded down $2.40 during trading hours on Monday, hitting $38.00. The company had a trading volume of 54,542 shares, compared to its average volume of 59,907. The firm’s fifty day moving average is $36.64 and its 200-day moving average is $28.44. Nanobiotix has a fifty-two week low of $4.10 and a fifty-two week high of $57.14.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $3.42 million for the quarter. On average, research analysts predict that Nanobiotix will post 0.19 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Guggenheim increased their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. UBS Group boosted their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Finally, TD Cowen restated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Nanobiotix currently has an average rating of “Moderate Buy” and a consensus target price of $26.67.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.